These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19861919)

  • 1. MET receptor tyrosine kinase.
    Faoro L; Cervantes GM; El-Hashani E; Salgia R
    J Thorac Oncol; 2009 Nov; 4(11 Suppl 3):S1064-5. PubMed ID: 19861919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Met inhibition.
    Salgia R
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):823-4. PubMed ID: 17143251
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Geynisman DM; Salgia R
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1810-1. PubMed ID: 22005540
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress on treatment of MET signaling pathway in non-small cell lung cancer.
    Yu X; Yu S; Fan Y
    Int J Clin Oncol; 2020 Aug; 25(8):1450-1458. PubMed ID: 32440811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.
    Riess JW; Neal JW
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1797-8. PubMed ID: 22005534
    [No Abstract]   [Full Text] [Related]  

  • 6. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
    Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
    Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET-Mutated NSCLC with Major Response to Crizotinib.
    Mendenhall MA; Goldman JW
    J Thorac Oncol; 2015 May; 10(5):e33-e34. PubMed ID: 25898965
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting the HGF/c-Met axis: state of play.
    Yap TA; de Bono JS
    Mol Cancer Ther; 2010 May; 9(5):1077-9. PubMed ID: 20442310
    [No Abstract]   [Full Text] [Related]  

  • 10. [Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer].
    Jiang T; Zhou C
    Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):240-4. PubMed ID: 25936889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].
    Yu X; Xu Y; Fan Y
    Zhongguo Fei Ai Za Zhi; 2017 Apr; 20(4):287-292. PubMed ID: 28442019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.
    Ma PC
    Cancer Discov; 2015 Aug; 5(8):802-5. PubMed ID: 26243862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
    Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
    Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Salgia R
    J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S372-4. PubMed ID: 23160322
    [No Abstract]   [Full Text] [Related]  

  • 15. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma.
    Yoshimura K; Karayama M; Inoue Y; Kahyo T; Inui N; Maekawa M; Sugimura H; Suda T
    Lung Cancer; 2018 Oct; 124():317-319. PubMed ID: 29573824
    [No Abstract]   [Full Text] [Related]  

  • 17. MET inhibitors start on road to recovery.
    Garber K
    Nat Rev Drug Discov; 2014 Aug; 13(8):563-5. PubMed ID: 25082276
    [No Abstract]   [Full Text] [Related]  

  • 18. Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.
    Womack JP; Varella-Garcia M; Camidge DR
    J Thorac Oncol; 2015 Dec; 10(12):e115-8. PubMed ID: 26709484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
    Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
    Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.